LEAP2 come bersaglio terapeutico nell'obesità e nei disturbi cardio-metabolici.

Obesity is a global public health challenge intimately linked to cardiometabolic complications. Although current anti-obesity medications can produce substantial and rapid weight loss, their discontinuation often results in rapid weight regain, underscoring the urgent need for therapies that support long-term weight loss maintenance. The ghrelin receptor system, comprising the hormone ghrelin and its receptor growth hormone secretagogue receptor 1a (GHSR1a), has long been a target for appetite regulation, but decades of drug development have yielded limited clinical success. The recent discovery of liver-expressed antimicrobial peptide 2 (LEAP2), an endogenous GHSR1a antagonist and inverse a